Latest Research Partnerships News

Nexsen has locked in over $1.5 million in non-dilutive funding through a national research partnership, accelerating manufacturing scale-up and platform optimisation for its rapid diagnostics technology.

NoviqTech Limited has clarified that its planned divestment of Non-Coralia assets was not foreseen during its Coralia acquisition and reflects a strategic pivot to biochar carbon removal, with leadership changes aligned to this refocus.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Micro-X has captured the first human head images using its innovative carbon nanotube cone beam CT technology, marking a major technical milestone as it launches a multi-centre pilot study aimed at stroke diagnosis.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

NoviqTech Limited attributes its recent share price jump and trading volume spike to earlier announcements about pivotal biochar trials and a major carbon removal offtake by Lufthansa Group, affirming its compliance with ASX rules.

Mount Ridley Mines has launched its first major metallurgical testwork program at the Grass Patch Heavy Rare Earth Element Project, targeting processing pathways for its regolith-hosted rare earth, scandium, and gallium mineralisation.

Pure Resources has launched an integrated Defence Materials Platform Strategy for its Garnet Hills Project, leveraging US government collaborations to diversify from commodity mining into advanced defence supply chains.

NoviqTech (ASX: NVQ) advances its biochar carbon removal strategy with a key non-binding MoU covering 70% of credits from its Great Barrier Reef project, targeting 2026 commercial milestones.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

iTech Minerals is gearing up for a major drilling campaign at its Northern Territory gold-antimony project, while its South Australian graphite asset shows promising metallurgical progress towards battery-grade products.

Locksley Resources has kicked off maiden diamond drilling at its Desert Antimony Mine and El Campo Rare Earth Element Prospect, alongside producing 99.5% purity antimony trioxide, reinforcing its push for a US domestic critical minerals supply chain.